Andrea B. Apolo, M.D.
Dr. Apolo is dedicated to improving the lives of patients with genitourinary tumors. Her research involves designing and implementing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is developing targeted therapies for bladder cancer and rare genitourinary tumors, including angiogenesis inhibitors, agents that target MET, and immunotherapies and in identifying molecular alterations that will serve as targets for individualized treatment strategies.
Appointments: For new patient referrals please contact Cynthia Boyle, RN, or Maureen Edgerly, RN, at 240-760-6050 or NCIMO_Referrals@mail.nih.gov
Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus ObservationOpen - RecruitingNCI Protocol ID NCI-18-C-0008Investigator Andrea B. Apolo, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Marissa Mallek 240-760-7498
Open - RecruitingNCI Protocol ID NCI-16-C-0121Investigator Andrea B. Apolo, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Deborah Allen 240.760.6184
A Phase I Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary TumorsOpen - RecruitingNCI Protocol ID NCI-15-C-0160Investigator Andrea B. Apolo, M.D.
Dr. Apolo is dedicated to improving the treatment and survival of patients with genitourinary tumors. Her research involves developing and designing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is in bladder cancer (urothelial carcinoma) and prostate cancer. In particular, she is working to develop new bladder cancer therapies that use targeted agents including anti-angiogenesis compounds, which block the growth of new blood vessels that feed tumors. Other research focuses include improving tumor detection by using new imaging modalities in bladder and prostate cancer and identifying molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies in patients with this disease. Dr. Apolo is fluent in both English and Spanish. Appointments: Laura D. Otten, RN, BSN, OCN (301) 451-1228 or toll-free 1-866-611-6310
Selected Recent Publications
Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.Thyroid. 24: 1223-31, 2014. [ Journal Article ]
Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer.J. Clin. Oncol. 32: 1868-70, 2014. [ Journal Article ]
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.Urol. Oncol. 32: 637-44, 2014. [ Journal Article ]
- Curr Probl Cancer. 38: 80-108, 2014. [ Journal Article ]
- Adv Urol. 2014: [Epub ahead of print], 2014. [ Journal Article ]
Dr. Apolo is a graduate of Albert Einstein College of Medicine in New York. She completed clinical training in internal medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center. Following her residency, she completed a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Apolo joined the Medical Oncology Branch of the National Cancer Institute as an assistant clinical investigator. She is board certified for the practice of internal medicine and medical oncology and is a participating member of the American Society for Clinical Oncology.
|Deborah Allen RN||Research Nurse Specialist|
|Rene Costello||Medical Technologist|
|Carlos Diaz||Patient Care Coordinator (Contr.)|
|Katie Graap RN||Research Nurse Specialist|
|Gloria L. Jackson MSN, CRNP, AOCNP||Nurse Practitioner (Contr.)|
|Corrine Keen RN||Supervisory Research Nurse Specialist|
|Elizabeth A. Lamping RN, BSN||Research Nurse Specialist|
|Marissa Mallek RN||Research Nurse Specialist|